BeyondSpring is a biopharmaceutical company that focuses on cancer therapies through the development of immune-modulating microtubule-binding agent called Plinabulin. The company also develops Plinabulin in combination with other immuno-oncology agents as well as three small molecule immune agents in preclinical stages. Founded in 2010, BeyondSpring is headquartered in New York, New York.